Akero Therapeutics: Funding, Investors & Team (Oct 2026)
Akero Therapeutics is dedicated to providing effective treatment options for individuals suffering from serious metabolic disorders like non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage that can lead to severe complications. The company is working on innovative medications that aim to restore metabolic balance and stop the progression of NASH. Their primary clinical program, AKR-001, is a modified FGF21 protein that has the potential to be the leading treatment for NASH. This drug draws from extensive research on FGF21 biology and is designed to target both the liver and fat tissue, reducing liver fat and inflammation while preventing fibrosis.
Akero Therapeutics has raised $743M across 4 funding rounds on record, the most recent an undisclosed round of $319M announced in Mar 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Akero Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Akero Therapeutics Funding Rounds
Akero Therapeutics raised $100M in a Post-IPO Debt announced in Jun 2022.
3 months later, a Post-IPO Equity of $200M was announced in Sep 2022.
8 months later, an undisclosed round of $124M was announced in May 2023.
10 months later, an undisclosed round of $319M was announced in Mar 2024.
Akero Therapeutics Founders and Leadership Team
Contact details for the Akero Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Akero Therapeutics Funding Compared to Other Biotechnology Startups
Akero Therapeutics' latest round of $319M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Akero Therapeutics in Biotechnology and Cambridge
Companies Similar to Akero Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Akero Therapeutics Funding FAQs
What does Akero Therapeutics do?
Akero Therapeutics is dedicated to providing effective treatment options for individuals suffering from serious metabolic disorders like non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage that can lead to severe complications. The company is working on innovative medications that aim to restore metabolic balance and stop the progression of NASH. Their primary clinical program, AKR-001, is a modified FGF21 protein that has the potential to be the leading treatment for NASH. This drug draws from extensive research on FGF21 biology and is designed to target both the liver and fat tissue, reducing liver fat and inflammation while preventing fibrosis.
How much funding has Akero Therapeutics raised?
Akero Therapeutics has raised $743M across 4 rounds on record. The most recent is an undisclosed round of $319M announced in Mar 2024.
When did Akero Therapeutics last raise funding?
Akero Therapeutics' most recent funding round on record is an undisclosed round of $319M, announced in Mar 2024.
Who founded Akero Therapeutics?
FundedIQ lists Tim Rolph (Founder) at Akero Therapeutics.
Where is Akero Therapeutics headquartered?
Akero Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Akero Therapeutics have?
Akero Therapeutics is in the 11-50 employee band.
How does Akero Therapeutics' funding compare to other Biotechnology startups?
Akero Therapeutics' latest round of $319M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Akero Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Akero Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.